ClinicalTrials.Veeva

Menu

Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations

B

Basharat Hussain

Status and phase

Not yet enrolling
Phase 2

Conditions

Lymphatic Abnormality

Treatments

Drug: doxycycline (tetracycline)
Drug: Bleomycin

Study type

Interventional

Funder types

Other

Identifiers

NCT07320001
BH-RCT-01

Details and patient eligibility

About

This is a randomized clinical trial comparing the safety and effectiveness of injection sclerotherapy using bleomycin versus doxycycline in children under 12 years with lymphatic malformations. The study will assess reduction in lesion size, clinical improvement, and treatment-related complications over six months.

Full description

This randomized clinical trial aims to compare the effectiveness and safety of injection sclerotherapy using bleomycin versus doxycycline in pediatric patients under 12 years of age diagnosed with lymphatic malformations. Eligible participants will be randomly assigned to receive either bleomycin or doxycycline injections at Holy family hospital Rawalpindi Pakistan.

The study will monitor participants over a six-month follow-up period to assess primary outcomes, including reduction in lesion size and clinical improvement, as well as secondary outcomes such as treatment-related complications, number of treatment sessions required, and overall patient tolerance.

Standard hospital protocols for injection sclerotherapy will be followed, and safety will be monitored by the principal investigator and treating physicians. Participants' caregivers will provide informed consent prior to enrollment. This study is designed to provide evidence on the comparative effectiveness of bleomycin versus doxycycline for pediatric lymphatic malformations

Enrollment

92 estimated patients

Sex

All

Ages

Under 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 0-12 years Radiological diagnosis of macrocytic/mixed lymphatic malformations. No prior sclerotherapy/surgical treatment. Informed consent from guardians

-

Exclusion criteria

  • microcytic lymphatic malformations Allergies to bleomycin/Doxycycline. Significant co morbidities Active infection at lesion site.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

92 participants in 2 patient groups

Bleomycin sclerotherapy
Active Comparator group
Treatment:
Drug: Bleomycin
Doxycycline sclerotherapy
Experimental group
Treatment:
Drug: doxycycline (tetracycline)

Trial contacts and locations

0

Loading...

Central trial contact

Basharat Hussain

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems